Merck’s singulair patent valid in the US
A CNN report has word that a US federal court trial judge has upheld the validity of Merck’s singulair patent. The Israeli firm Teva had sought to bring a generic version to market. Merck was quite confident:
In July, Chief Executive Richard Clark said in an interview the company had no contingency plan in the event of a loss, saying “if you feel you have a very strong position, you don’t need a contingency plan.”
